» Articles » PMID: 38052860

Diagnostic Accuracy and the First Genotype-phenotype Correlation in Glycogen Storage Disease Type V

Abstract

Background: Glycogen storage disease type V (GSDV) is an autosomal recessive metabolic condition caused by pathogenic PYGM variants. This is an underdiagnosed condition as it presents with exercise intolerance in children. We reviewed the GSDV cases of a tertiary hospital center to assess diagnostic timing/accuracy, as well as potential clinical/analytical predictors of such factors.

Methods: We retrospectively reviewed all GSDV cases with follow-up in both Pediatric and Adult Metabolic Diseases consultations. We included 28 cases and assessed their hospital record for clinical information.

Results: Over 90% of our cases had late diagnoses, with more than 50% being diagnosed in adulthood despite symptom onset in preschool (very late diagnosis). Diagnostic age was lower in patients exhibiting myoglobinuria. Interestingly, patients with a positive family history of GSDV had similar rates of very late diagnoses, likely since the index case was already detected very late in life. Finally, we observe that the R50* variant is associated with increased myoglobinuria and CK elevation, in a dosage-dependent manner.

Conclusion: We concluded that GSDV is severely underdiagnosed, and that some clinical and analytical aspects of the condition can be more indicative of this diagnosis. Furthermore, we propose for the first time a genotype-phenotype correlation in GSDV.

Impact: GSDV is a pediatric-onset metabolic disorder that is mostly diagnosed late in the adult age and commonly misdiagnosed. We observed the first genotype-phenotype correlation in GSDV, regarding the common R50* variant. Awareness of GSDV for pediatricians and the overall medical community is vital.

Citing Articles

Mitochondrial Dysfunction in Glycogen Storage Disorders (GSDs).

Mishra K, Kakhlon O Biomolecules. 2024; 14(9).

PMID: 39334863 PMC: 11430448. DOI: 10.3390/biom14091096.


Glycogen storage disease type V: a still under-recognized condition lacking definitive genotype-phenotype correlates.

Ravaglia S, Gana S, Valente E Pediatr Res. 2024; 96(2):279-280.

PMID: 38514859 DOI: 10.1038/s41390-024-03149-9.

References
1.
Vieitez I, Teijeira S, Fernandez J, San Millan B, Miranda S, Ortolano S . Molecular and clinical study of McArdle's disease in a cohort of 123 European patients. Identification of 20 novel mutations. Neuromuscul Disord. 2011; 21(12):817-23. DOI: 10.1016/j.nmd.2011.07.002. View

2.
Lucia A, Ruiz J, Santalla A, Nogales-Gadea G, Rubio J, Garcia-Consuegra I . Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012; 83(3):322-8. DOI: 10.1136/jnnp-2011-301593. View

3.
Lucia A, Martinuzzi A, Nogales-Gadea G, Quinlivan R, Reason S . Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul Disord. 2021; 31(12):1296-1310. DOI: 10.1016/j.nmd.2021.10.006. View

4.
Milstein J, Herron T, Haas J . Fatal infantile muscle phosphorylase deficiency. J Child Neurol. 1989; 4(3):186-8. DOI: 10.1177/088307388900400305. View

5.
Bartram C, EDWARDS R, Clague J, Beynon R . McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet. 1993; 2(8):1291-3. DOI: 10.1093/hmg/2.8.1291. View